$BCLI
BRAINSTORM CELL THERAPEUTICS INC. Stock $bcli

$bcli Overview Financials Valuation SEC Filings Company Website

2013 Q3 Form 10-Q Financial Statement

#000114420413061876 Filed on November 14, 2013

Income Statement

Concept	2013 Q3	2012 Q3	2012 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$270.0K	$440.0K	$450.0K
YoY Change	-38.64%	-21.43%	-29.69%
% of Gross Profit
Research & Development	$804.0K	$732.0K	$385.0K
YoY Change	9.84%	306.67%	-34.75%
% of Gross Profit
Depreciation & Amortization	$30.00K	$40.00K	$40.00K
YoY Change	-25.0%	0.0%	0.0%
% of Gross Profit
Operating Expenses	$1.076M	$1.172M	$833.0K
YoY Change	-8.19%	58.38%	-31.72%
Operating Profit	-$1.081M	-$1.150M	-$829.0K
YoY Change	-6.0%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$10.00K	$20.00K	$0.00
YoY Change	-150.0%	-60.0%	-100.0%
Pretax Income	-$1.080M	-$1.150M	-$830.0K
YoY Change	-6.09%	66.67%	-23.85%
Income Tax	$1.000K	$0.00	$1.000K
% Of Pretax Income
Net Earnings	-$1.082M	-$1.150M	-$830.0K
YoY Change	-5.91%	66.67%	-24.55%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$98.63K	-$118.7K	-$97.19K
COMMON SHARES
Basic Shares Outstanding	152.7M shares		128.6M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q3	2012 Q3	2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.120M	$4.780M	$840.0K
YoY Change	7.11%	100.0%	-71.03%
Cash & Equivalents	$329.0K	$4.783M	$843.0K
Short-Term Investments	$4.790M
Other Short-Term Assets	$60.00K	$50.00K	$140.0K
YoY Change	20.0%	25.0%	180.0%
Inventory
Prepaid Expenses	$55.00K
Receivables	$500.0K	$450.0K	$420.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$5.672M	$5.290M	$1.400M
YoY Change	7.22%	88.93%	-55.27%
LONG-TERM ASSETS
Property, Plant & Equipment	$267.0K	$270.0K	$300.0K
YoY Change	-1.11%	-20.59%	-21.05%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$20.00K	$20.00K
YoY Change		100.0%	100.0%
Other Assets	$270.0K	$150.0K	$130.0K
YoY Change	80.0%	50.0%	44.44%
Total Long-Term Assets	$540.0K	$430.0K	$450.0K
YoY Change	25.58%	-4.44%	-8.16%
TOTAL ASSETS
Total Short-Term Assets	$5.672M	$5.290M	$1.400M
Total Long-Term Assets	$540.0K	$430.0K	$450.0K
Total Assets	$6.212M	$5.720M	$1.850M
YoY Change	8.6%	76.0%	-48.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$446.0K	$190.0K	$520.0K
YoY Change	134.74%	18.75%	73.33%
Accrued Expenses	$710.0K	$830.0K	$790.0K
YoY Change	-14.46%	48.21%	31.67%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.386M	$1.100M	$1.450M
YoY Change	26.0%	35.8%	13.28%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$290.0K	$160.0K	$150.0K
YoY Change	81.25%	60.0%	66.67%
Total Long-Term Liabilities	$290.0K	$160.0K	$150.0K
YoY Change	81.25%	60.0%	66.67%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.386M	$1.100M	$1.450M
Total Long-Term Liabilities	$290.0K	$160.0K	$150.0K
Total Liabilities	$1.677M	$1.260M	$1.600M
YoY Change	33.1%	38.46%	16.79%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock	$55.73M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.535M	$4.460M	$250.0K
YoY Change
Total Liabilities & Shareholders Equity	$6.212M	$5.720M	$1.850M
YoY Change	8.6%	76.0%	-48.9%

Cashflow Statement

Concept	2013 Q3	2012 Q3	2012 Q2
OPERATING ACTIVITIES
Net Income	-$1.082M	-$1.150M	-$830.0K
YoY Change	-5.91%	66.67%	-24.55%
Depreciation, Depletion And Amortization	$30.00K	$40.00K	$40.00K
YoY Change	-25.0%	0.0%	0.0%
Cash From Operating Activities	-$713.0K	-$1.074M	-$419.0K
YoY Change	-33.61%	20.67%	-47.63%
INVESTING ACTIVITIES
Capital Expenditures	$31.00K	$14.00K	$9.000K
YoY Change	121.43%
Acquisitions
YoY Change
Other Investing Activities	-$3.010M	$0.00	$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$3.039M	-$14.00K	-$9.000K
YoY Change	21607.14%		-10.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$3.326M	$4.900M	$0.00
YoY Change	-32.12%	1156.41%	-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$3.326M	$5.028M	$126.0K
YoY Change	-33.85%	1189.23%	152.0%
NET CHANGE
Cash From Operating Activities	-$713.0K	-$1.074M	-$419.0K
Cash From Investing Activities	-$3.039M	-$14.00K	-$9.000K
Cash From Financing Activities	$3.326M	$5.028M	$126.0K
Net Change In Cash	-$426.0K	$3.940M	-$302.0K
YoY Change	-110.81%	-888.0%	-60.26%
FREE CASH FLOW
Cash From Operating Activities	-$713.0K	-$1.074M	-$419.0K
Capital Expenditures	$31.00K	$14.00K	$9.000K
Free Cash Flow	-$744.0K	-$1.088M	-$428.0K
YoY Change	-31.62%	22.25%	-46.5%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q3	us-gaap	Short Term Investments ShortTermInvestments	4786000	USD
CY2012Q4	us-gaap	Short Term Investments ShortTermInvestments	2769000	USD
CY2013Q3	us-gaap	Nontrade Receivables Current NontradeReceivablesCurrent	502000	USD
CY2012Q4	us-gaap	Nontrade Receivables Current NontradeReceivablesCurrent	742000	USD
CY2013Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	55000	USD
CY2012Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	46000	USD
CY2013Q3	us-gaap	Assets Current AssetsCurrent	5672000	USD
CY2010	us-gaap	Net Income Loss NetIncomeLoss	-2419000	USD
CY2010Q4	us-gaap	Stockholders Equity StockholdersEquity	-459000	USD
CY2011	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	449000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1574000	USD
CY2013Q3	us-gaap	Liabilities Liabilities	1677000	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	358000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	1328000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	28257000	USD
CY2011	bcli	Stock Based Compensation Related To Options Granted To Employees And Directors Value StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue	1135000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2068000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1486000	USD
CY2013Q3	us-gaap	Common Stock Value CommonStockValue	8000	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	7000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1397000	USD
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	272000	USD
CY2013Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	446000	USD
CY2013Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	710000	USD
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	605000	USD
CY2013Q3	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	230000	USD
CY2012Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	176000	USD
CY2013Q3	us-gaap	Long Term Investments LongTermInvestments	273000	USD
CY2012Q4	us-gaap	Long Term Investments LongTermInvestments	189000	USD
CY2013Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	267000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	247000	USD
CY2013Q3	us-gaap	Assets Assets	6212000	USD
CY2012Q4	us-gaap	Assets Assets	5310000	USD
CY2013Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1386000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1139000	USD
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	51483000	USD
CY2013Q3	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	51190000	USD
CY2012Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	47508000	USD
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	4535000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	3982000	USD
CY2013Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6212000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5310000	USD
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	804000	USD
CY2012Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	732000	USD
CY2012Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	440000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	4874000	USD
CY2013Q3	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	28000	USD
CY2012Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	17000	USD
CY2013Q3	bcli	Severance Pay Fund SeverancePayFund	245000	USD
CY2012Q4	bcli	Severance Pay Fund SeverancePayFund	172000	USD
CY2013Q3	us-gaap	Other Postretirement Defined Benefit Plan Liabilities Noncurrent OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent	291000	USD
CY2012Q4	us-gaap	Other Postretirement Defined Benefit Plan Liabilities Noncurrent OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent	189000	USD
CY2013Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	55717000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20325000	USD
	us-gaap	Operating Expenses OperatingExpenses	3642000	USD
	us-gaap	Operating Expenses OperatingExpenses	2883000	USD
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	1076000	USD
CY2012Q3	us-gaap	Operating Expenses OperatingExpenses	1172000	USD
	us-gaap	Operating Expenses OperatingExpenses	48582000	USD
	bcli	Financial Expenses Income Net FinancialExpensesIncomeNet	21000	USD
	bcli	Financial Expenses Income Net FinancialExpensesIncomeNet	-37000	USD
CY2013Q3	bcli	Financial Expenses Income Net FinancialExpensesIncomeNet	5000	USD
CY2012Q3	bcli	Financial Expenses Income Net FinancialExpensesIncomeNet	-22000	USD
	bcli	Financial Expenses Income Net FinancialExpensesIncomeNet	2475000	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	USD
CY2013Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	USD
CY2012Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	132000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3663000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2846000	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1081000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-50925000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	19000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5000	USD
CY2013Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000	USD
CY2012Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	101000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-3682000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-2851000	USD
CY2013Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-1082000	USD
CY2012Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-1150000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-51026000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
CY2013Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
CY2012Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-164000	USD
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.02
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.02
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-1082000	USD
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1150000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	440000	USD
CY2013Q3	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	-75000	USD
CY2012Q3	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	127000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	7820000	USD
CY2001Q1	us-gaap	Stockholders Equity StockholdersEquity	68000	USD
CY2002	bcli	Adjustments To Additional Paid In Capital Contribution Of Capital AdjustmentsToAdditionalPaidInCapitalContributionOfCapital	11000	USD
CY2002	us-gaap	Net Income Loss NetIncomeLoss	-26000	USD
CY2002Q1	us-gaap	Stockholders Equity StockholdersEquity	53000	USD
CY2003	bcli	Adjustments To Additional Paid In Capital Contribution Of Capital AdjustmentsToAdditionalPaidInCapitalContributionOfCapital	15000	USD
CY2003	us-gaap	Net Income Loss NetIncomeLoss	-47000	USD
CY2003Q1	us-gaap	Stockholders Equity StockholdersEquity	21000	USD
	bcli	Increase In Accounts Receivable And Prepaid Expenses IncreaseInAccountsReceivableAndPrepaidExpenses	-231000	USD
	bcli	Increase In Accounts Receivable And Prepaid Expenses IncreaseInAccountsReceivableAndPrepaidExpenses	121000	USD
CY2013Q3	bcli	Increase In Accounts Receivable And Prepaid Expenses IncreaseInAccountsReceivableAndPrepaidExpenses	-198000	USD
CY2012Q3	bcli	Increase In Accounts Receivable And Prepaid Expenses IncreaseInAccountsReceivableAndPrepaidExpenses	-56000	USD
	bcli	Increase In Accounts Receivable And Prepaid Expenses IncreaseInAccountsReceivableAndPrepaidExpenses	557000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	88000	USD
CY2004	bcli	Stock Issued During Period Value Stock Splits StockIssuedDuringPeriodValueStockSplits	0	USD
CY2004	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	6000	USD
CY2004	bcli	Stock Cancelled During Period Value StockCancelledDuringPeriodValue	0	USD
CY2004	bcli	Adjustments To Additional Paid In Capital Contribution Of Capital AdjustmentsToAdditionalPaidInCapitalContributionOfCapital	15000	USD
CY2004	us-gaap	Net Income Loss NetIncomeLoss	-73000	USD
CY2004Q1	us-gaap	Stockholders Equity StockholdersEquity	-31000	USD
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	77000	USD
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	116000	USD
CY2013Q3	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	27000	USD
CY2012Q3	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	40000	USD
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	1235000	USD
	us-gaap	Severance Costs1 SeveranceCosts1	29000	USD
	us-gaap	Severance Costs1 SeveranceCosts1	6000	USD
CY2013Q3	us-gaap	Severance Costs1 SeveranceCosts1	22000	USD
CY2012Q3	us-gaap	Severance Costs1 SeveranceCosts1	5000	USD
	us-gaap	Severance Costs1 SeveranceCosts1	46000	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	USD
CY2013Q3	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	USD
CY2012Q3	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	USD
CY2013Q3	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.01
CY2012Q3	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.01
	us-gaap	Net Income Loss NetIncomeLoss	-3682000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-2851000	USD
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	-1150000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-51190000	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	152094266	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	133403123	shares
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	164223127	shares
CY2012Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	145407840	shares
	bcli	Stock Issued During Period For Cash In September Price Per Share StockIssuedDuringPeriodForCashInSeptemberPricePerShare	0.00188
	bcli	Stock Issued During Period For Cash In March Price Per Share StockIssuedDuringPeriodForCashInMarchPricePerShare	0.0375
CY2004	bcli	Price Per Share Of Stock Issued During Period To Purchase Mineral Option PricePerShareOfStockIssuedDuringPeriodToPurchaseMineralOption	0.065
CY2000Q3	us-gaap	Stockholders Equity StockholdersEquity	0	USD
	bcli	Stock Issued During Period For Cash In September StockIssuedDuringPeriodForCashInSeptember	17000	USD
	bcli	Stock Issued During Period For Cash In March StockIssuedDuringPeriodForCashInMarch	60000	USD
	bcli	Adjustments To Additional Paid In Capital Contribution Of Capital AdjustmentsToAdditionalPaidInCapitalContributionOfCapital	8000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-17000	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	451000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2012Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1864000	USD
	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	0	USD
	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	0	USD
CY2013Q3	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	0	USD
CY2012Q3	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	0	USD
	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	795000	USD
	bcli	Expenses Related To Shares And Options Granted To Service Providers ExpensesRelatedToSharesAndOptionsGrantedToServiceProviders	213000	USD
	bcli	Erosion Of Restricted Cash ErosionOfRestrictedCash	0	USD
	bcli	Erosion Of Restricted Cash ErosionOfRestrictedCash	0	USD
CY2013Q3	bcli	Erosion Of Restricted Cash ErosionOfRestrictedCash	0	USD
CY2012Q3	bcli	Erosion Of Restricted Cash ErosionOfRestrictedCash	0	USD
	bcli	Erosion Of Restricted Cash ErosionOfRestrictedCash	6000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2446000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2239000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-50000	USD
CY2013Q3	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	73000	USD
CY2012Q3	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-321000	USD
CY2013Q3	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-713000	USD
CY2012Q3	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1074000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-16709000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	0	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	0	USD
CY2013Q3	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	0	USD
CY2012Q3	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	0	USD
	bcli	Expenses Related To Shares And Options Granted To Service Providers ExpensesRelatedToSharesAndOptionsGrantedToServiceProviders	46000	USD
CY2013Q3	bcli	Expenses Related To Shares And Options Granted To Service Providers ExpensesRelatedToSharesAndOptionsGrantedToServiceProviders	11000	USD
CY2012Q3	bcli	Expenses Related To Shares And Options Granted To Service Providers ExpensesRelatedToSharesAndOptionsGrantedToServiceProviders	38000	USD
	bcli	Expenses Related To Shares And Options Granted To Service Providers ExpensesRelatedToSharesAndOptionsGrantedToServiceProviders	21894000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	439000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-23000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2446000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	919000	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	159000	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	175000	USD
CY2013Q3	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	113000	USD
CY2012Q3	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	131000	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	1446000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2239000	USD
CY2013Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-713000	USD
CY2012Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1074000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16732000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	97000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	75000	USD
CY2013Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	31000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1320000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
CY2013Q3	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-6000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	2017000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	USD
CY2013Q3	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	3006000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	4786000	USD
	bcli	Investment In Lease Deposit InvestmentInLeaseDeposit	-11000	USD
	bcli	Investment In Lease Deposit InvestmentInLeaseDeposit	0	USD
CY2013Q3	bcli	Investment In Lease Deposit InvestmentInLeaseDeposit	-2000	USD
	bcli	Investment In Lease Deposit InvestmentInLeaseDeposit	-28000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-2125000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-75000	USD
CY2013Q3	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-3039000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-6128000	USD
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	0	USD
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	0	USD
CY2013Q3	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	0	USD
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-16000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2125000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-75000	USD
CY2013Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3039000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6144000	USD
CY2012Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14000	USD
CY2012Q3	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
CY2013Q3	us-gaap	Repayments Of Other Short Term Debt RepaymentsOfOtherShortTermDebt	0	USD
	us-gaap	Repayments Of Other Short Term Debt RepaymentsOfOtherShortTermDebt	0	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-426000	USD
CY2012Q3	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	USD
CY2012Q3	bcli	Investment In Lease Deposit InvestmentInLeaseDeposit	0	USD
CY2012Q3	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-14000	USD
CY2012Q3	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	0	USD
CY2012Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3576000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5028000	USD
CY2013Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3326000	USD
CY2012Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5028000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	20918000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt And Capital Securities Net ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet	0	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt And Capital Securities Net ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet	0	USD
CY2013Q3	us-gaap	Proceeds From Issuance Of Long Term Debt And Capital Securities Net ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet	0	USD
CY2012Q3	us-gaap	Proceeds From Issuance Of Long Term Debt And Capital Securities Net ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet	0	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt And Capital Securities Net ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet	2061000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	7000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	146000	USD
CY2013Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	USD
CY2012Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	784000	USD
	us-gaap	Repayments Of Other Short Term Debt RepaymentsOfOtherShortTermDebt	0	USD
CY2012Q3	us-gaap	Repayments Of Other Short Term Debt RepaymentsOfOtherShortTermDebt	0	USD
	us-gaap	Repayments Of Other Short Term Debt RepaymentsOfOtherShortTermDebt	601000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	3583000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	5174000	USD
CY2013Q3	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	3326000	USD
CY2012Q3	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	5028000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	23162000	USD
	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	0	USD
	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	0	USD
CY2013Q3	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	0	USD
CY2012Q3	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	0	USD
	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	43000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3583000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5174000	USD
CY2013Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3326000	USD
CY2012Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5028000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	23205000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-988000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2860000	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	3940000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	329000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1923000	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	755000	USD
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	843000	USD
CY2000Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	0	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4783000	USD
CY2013Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2004Q2	bcli	Common Stock Transferred As Per Purchase Agreement CommonStockTransferredAsPerPurchaseAgreement	6880000	shares
	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	between 1-for-10 and 1-for-20
CY2012Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5700000	USD
CY2013Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4000000	USD
CY2009Q4	bcli	Research License Agreement Expenses Paid ResearchLicenseAgreementExpensesPaid	400000	USD
CY2009Q4	bcli	Obligation Amount To Fund Extended Research Period ObligationAmountToFundExtendedResearchPeriod	1140000	USD
CY2009	bcli	Research And Development Expenses Reversed ResearchAndDevelopmentExpensesReversed	760000	USD
CY2009	bcli	Research License Interest Rate ResearchLicenseInterestRate	32000	USD
CY2009	bcli	Shares Granted As Per Research And License Agreement SharesGrantedAsPerResearchAndLicenseAgreement	1120000	shares
CY2009	bcli	Number Of Days Of Restriction To Sell Shares In Open Market NumberOfDaysOfRestrictionToSellSharesInOpenMarket	P185D
CY2009	bcli	Stock Based Compensation Related To Shares Granted Under Research License Agreement StockBasedCompensationRelatedToSharesGrantedUnderResearchLicenseAgreement	51000	USD
CY2011Q1	bcli	Number Of Shares Sold By Purchaser As Permitted By Settlement Agreement NumberOfSharesSoldByPurchaserAsPermittedBySettlementAgreement	167530	shares
CY2011Q1	bcli	Proceeds From Shares Sold By Purchaser As Permitted By Settlement Agreement ProceedsFromSharesSoldByPurchaserAsPermittedBySettlementAgreement	35000	USD
CY2011Q1	bcli	Total Value Of Shares Sold By Purchaser TotalValueOfSharesSoldByPurchaser	235000	USD
CY2011Q1	bcli	Research License Payments Made As Per Settlement Agreement ResearchLicensePaymentsMadeAsPerSettlementAgreement	5000	USD
	bcli	Percentage Of Royalty Payment If Licensed Product Covered By Valid Claim Or Orphan Drug Status PercentageOfRoyaltyPaymentIfLicensedProductCoveredByValidClaimOrOrphanDrugStatus	0.05	pure
	bcli	Percentage Of Royalty Payment If Licensed Product Not Covered By Valid Claim Or Orphan Drug Status PercentageOfRoyaltyPaymentIfLicensedProductNotCoveredByValidClaimOrOrphanDrugStatus	0.03	pure
	bcli	Validity Of Royalty Payment Not Covered By Valid Claim Or Orphan Drug Status ValidityOfRoyaltyPaymentNotCoveredByValidClaimOrOrphanDrugStatus	P15Y
CY2009	bcli	Proceeds From Sale Of Shares Are Less Than240 Conditions ProceedsFromSaleOfSharesAreLessThan240Conditions	Company would pay to Ramot the difference between the proceeds that Ramot has received from sales of the shares up to such date together with the September Payment (if any) that has been transferred to Ramot up to such date, and $240.
CY2011Q1	bcli	Amount Due To Investors AmountDueToInvestors	22000	USD
CY2010Q1	invest	Investment Warrants Exercise Price InvestmentWarrantsExercisePrice	0.50
CY2009	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	1120000	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.1803
CY2006	bcli	Price Per Share Of Stock Issued During Period For Private Placement In July PricePerShareOfStockIssuedDuringPeriodForPrivatePlacementInJuly	0.6
CY2006	bcli	Price Per Share Of Stock Issued During Period For Private Placement In September PricePerShareOfStockIssuedDuringPeriodForPrivatePlacementInSeptember	0.8
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4751665	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4626666	shares
	bcli	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	4006667	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5371664	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	4943609	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.2656
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.2898
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.1721
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	0.1764
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	96166000	USD
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	67341000	USD
	bcli	Number Of Warrants Issued Total NumberOfWarrantsIssuedTotal	112742177	shares
	bcli	Warrant Exercised Total WarrantExercisedTotal	16468540	shares
	bcli	Warrant Forfeited Total WarrantForfeitedTotal	27401794	shares
CY2013Q3	bcli	Warrants Outstanding Total WarrantsOutstandingTotal	68871843	shares
CY2013Q3	bcli	Warrants Exercisable Total WarrantsExercisableTotal	68352398	shares
	us-gaap	Share Based Compensation ShareBasedCompensation	622000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	485000	USD
CY2013Q3	us-gaap	Share Based Compensation ShareBasedCompensation	-64000	USD
CY2012Q3	us-gaap	Share Based Compensation ShareBasedCompensation	164000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	29294000	USD
CY2005	bcli	Price Per Share Of Stock Issued During Period For Private Placement In June PricePerShareOfStockIssuedDuringPeriodForPrivatePlacementInJune	0.01
CY2005	bcli	Stock Issued Expenses StockIssuedExpenses	25000	USD
CY2005	bcli	Price Per Share Of Stock Issued During Period For Private Placement Issue One PricePerShareOfStockIssuedDuringPeriodForPrivatePlacementIssueOne	0.75
CY2006	bcli	Price Per Share Of Stock Issued During Period For Private Placement In May PricePerShareOfStockIssuedDuringPeriodForPrivatePlacementInMay	0.8
CY2006	bcli	Price Per Share Of Stock Issued During Period For Private Placement In December PricePerShareOfStockIssuedDuringPeriodForPrivatePlacementInDecember	0.8
CY2005	bcli	Stock Issued During Period For Private Placement In June StockIssuedDuringPeriodForPrivatePlacementInJune	60000	USD
CY2005	bcli	Adjustments To Additional Paid In Capital Contribution Of Capital AdjustmentsToAdditionalPaidInCapitalContributionOfCapital	7000	USD
CY2005	bcli	Stock Issued During Period For Private Placement Value Issues One StockIssuedDuringPeriodForPrivatePlacementValueIssuesOne	1418000	USD
CY2005	bcli	Stock Cancelled During Period Value StockCancelledDuringPeriodValue	0	USD
CY2005	bcli	Stock Based Compensation Related To Options Granted To Employees And Directors Value StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue	0	USD
CY2005	bcli	Amortization Of Deferred Stock Based Compensation Related To Shares And Options Granted To Employees AmortizationOfDeferredStockBasedCompensationRelatedToSharesAndOptionsGrantedToEmployees	584000	USD
CY2005	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	17506000	USD
CY2005	us-gaap	Net Income Loss NetIncomeLoss	-18840000	USD
CY2005Q1	us-gaap	Stockholders Equity StockholdersEquity	704000	USD
CY2006	bcli	Stock Issued During Period For Private Placement In May StockIssuedDuringPeriodForPrivatePlacementInMay	149000	USD
CY2006	bcli	Stock Issued During Period For Private Placement In July StockIssuedDuringPeriodForPrivatePlacementInJuly	99000	USD
CY2006	bcli	Stock Issued During Period For Private Placement In September StockIssuedDuringPeriodForPrivatePlacementInSeptember	225000	USD
CY2006	bcli	Stock Issued During Period For Private Placement In December StockIssuedDuringPeriodForPrivatePlacementInDecember	135000	USD
CY2006	bcli	Forfeiture Of Options Granted To Employees ForfeitureOfOptionsGrantedToEmployees	0	USD
CY2006	bcli	Stock Based Compensation Related To Options Granted To Employees And Directors Value StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue	0	USD
CY2006	bcli	Amortization Of Deferred Stock Based Compensation Related To Shares And Options Granted To Employees AmortizationOfDeferredStockBasedCompensationRelatedToSharesAndOptionsGrantedToEmployees	1174000	USD
CY2011	bcli	Stock Issued During Period Value Conversion Of Convertible Note StockIssuedDuringPeriodValueConversionOfConvertibleNote	140000	USD
CY2011	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	243000	USD
CY2009	bcli	Adjustments To Additional Paid In Capital Subscription Of Shares For Private Placement AdjustmentsToAdditionalPaidInCapitalSubscriptionOfSharesForPrivatePlacement	729000	USD
CY2007	bcli	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	214000	USD
CY2006	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	662000	USD
CY2006	bcli	Adjustments To Additional Paid In Capital Reclassification Due To Application AdjustmentsToAdditionalPaidInCapitalReclassificationDueToApplication	-7906000	USD
CY2006	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	164000	USD
CY2006	us-gaap	Net Income Loss NetIncomeLoss	-3317000	USD
CY2006Q1	us-gaap	Stockholders Equity StockholdersEquity	-7911000	USD
	bcli	Elimination Of Deferred Stock Compensation Due To Implementation EliminationOfDeferredStockCompensationDueToImplementation	0	USD
	bcli	Stock Based Compensation Related To Options Granted To Employees And Directors Value StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue	1168000	USD
	bcli	Adjustments To Additional Paid In Capital Reclassification Due To Application AdjustmentsToAdditionalPaidInCapitalReclassificationDueToApplication	7191000	USD
	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	453000	USD
	bcli	Adjustments To Additional Paid In Capital Warrant Issued To Convertible Note Holder AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToConvertibleNoteHolder	11000	USD
	bcli	Adjustments To Additional Paid In Capital Warrant Issued To Loan Holder AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToLoanHolder	110000	USD
	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	1086000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-3924000	USD
CY2006Q4	us-gaap	Stockholders Equity StockholdersEquity	-1816000	USD
CY2007	bcli	Price Per Share Of Stock Issued During Period For Private Placement Issue One PricePerShareOfStockIssuedDuringPeriodForPrivatePlacementIssueOne	0.1818
CY2008	bcli	Price Per Share Of Stock Issued During Period For Private Placement Issue One PricePerShareOfStockIssuedDuringPeriodForPrivatePlacementIssueOne	0.1818
CY2008	bcli	Price Per Share Of Subscription Of Shares During Period For Private Placement PricePerShareOfSubscriptionOfSharesDuringPeriodForPrivatePlacement	0.1818
CY2007	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	1446000	USD
CY2007	bcli	Adjustments To Additional Paid In Capital Warrant Issued To Convertible Note Holder AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToConvertibleNoteHolder	109000	USD
CY2007	bcli	Stock Based Compensation Related To Options Granted To Employees And Directors Value StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue	1232000	USD
CY2007	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	407000	USD
CY2007	bcli	Stock Issued During Period For Private Placement Value StockIssuedDuringPeriodForPrivatePlacementValue	2000000	USD
CY2007	us-gaap	Net Income Loss NetIncomeLoss	-6244000	USD
CY2007Q4	us-gaap	Stockholders Equity StockholdersEquity	-2428000	USD
CY2008	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	33000	USD
CY2008	bcli	Stock Based Compensation Related To Options Granted To Employees And Directors Value StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue	731000	USD
CY2008	bcli	Stock Issued During Period Value Conversion Of Convertible Loans StockIssuedDuringPeriodValueConversionOfConvertibleLoans	1276000	USD
CY2007	bcli	Stock Issued During Period Value Conversion Of Convertible Loans StockIssuedDuringPeriodValueConversionOfConvertibleLoans	224000	USD
CY2008	bcli	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	0	USD
CY2008	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3000	USD
CY2008	bcli	Stock Issued During Period For Private Placement Value StockIssuedDuringPeriodForPrivatePlacementValue	1500000	USD
CY2008	bcli	Adjustments To Additional Paid In Capital Subscription Of Shares For Private Placement AdjustmentsToAdditionalPaidInCapitalSubscriptionOfSharesForPrivatePlacement	281000	USD
CY2008	us-gaap	Net Income Loss NetIncomeLoss	-3472000	USD
CY2008Q4	us-gaap	Stockholders Equity StockholdersEquity	-2076000	USD
CY2009	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	775000	USD
CY2009	bcli	Stock Based Compensation Related To Options Granted To Employees And Directors Value StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue	409000	USD
CY2009	bcli	Stock Issued During Period Value Conversion Of Convertible Loans StockIssuedDuringPeriodValueConversionOfConvertibleLoans	200000	USD
CY2009	bcli	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	0	USD
CY2009	bcli	Stock Issued During Period For Private Placement Value Issues One StockIssuedDuringPeriodForPrivatePlacementValueIssuesOne	1000	USD
CY2009	us-gaap	Net Income Loss NetIncomeLoss	-1781000	USD
CY2009Q4	us-gaap	Stockholders Equity StockholdersEquity	-1743000	USD
CY2010	bcli	Price Per Share Of Subscription Of Shares During Period For Private Placement PricePerShareOfSubscriptionOfSharesDuringPeriodForPrivatePlacement	0.12
CY2010	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	96000	USD
CY2010	bcli	Stock Based Compensation Related To Options Granted To Employees And Directors Value StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue	388000	USD
CY2010	bcli	Stock Issued During Period For Private Placement Value Issues One StockIssuedDuringPeriodForPrivatePlacementValueIssuesOne	1751000	USD
CY2010	bcli	Stock Issued During Period Value Conversion Of Convertible Note StockIssuedDuringPeriodValueConversionOfConvertibleNote	135000	USD
CY2010	bcli	Stock Issued During Period Value Conversion Of Convertible Loans StockIssuedDuringPeriodValueConversionOfConvertibleLoans	189000	USD
CY2010	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	400000	USD
CY2010	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	77000	USD
CY2010	bcli	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	11000	USD
CY2010	bcli	Adjustments To Additional Paid In Capital Subscription Of Shares For Private Placement AdjustmentsToAdditionalPaidInCapitalSubscriptionOfSharesForPrivatePlacement	455000	USD
CY2010	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	201000	USD
CY2010	bcli	Stock Issued During Period Value Previously Subscribed Shares StockIssuedDuringPeriodValuePreviouslySubscribedShares	0	USD
	bcli	Stock Issued During Period For Private Placement Value StockIssuedDuringPeriodForPrivatePlacementValue	250000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3326000	USD
	bcli	Stock Issued During Period Value Conversion Of Convertible Loans StockIssuedDuringPeriodValueConversionOfConvertibleLoans	30000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7000	USD
CY2011	bcli	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	272000	USD
CY2011	bcli	Stock Issued During Period For Private Placement Value StockIssuedDuringPeriodForPrivatePlacementValue	3602000	USD
CY2011	bcli	Stock Issued During Period Value Previously Subscribed Shares StockIssuedDuringPeriodValuePreviouslySubscribedShares	24000	USD
CY2011	us-gaap	Net Income Loss NetIncomeLoss	-3918000	USD
CY2012	bcli	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	9000	USD
CY2012	bcli	Stock Issued During Period For Private Placement Value StockIssuedDuringPeriodForPrivatePlacementValue	5023000	USD
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-3430000	USD
	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	183000	USD
	bcli	Stock Based Compensation Related To Options Granted To Employees And Directors Value StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue	439000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	1488000	USD
CY2012	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	195000	USD
CY2012	bcli	Stock Based Compensation Related To Options Granted To Employees And Directors Value StockBasedCompensationRelatedToOptionsGrantedToEmployeesAndDirectorsValue	560000	USD
CY2012	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	137000	USD

Files In Submission

Name	View Source	Status
0001144204-13-061876-index-headers.html	Edgar Link	pending
0001144204-13-061876-index.html	Edgar Link	pending
0001144204-13-061876.txt	Edgar Link	pending
0001144204-13-061876-xbrl.zip	Edgar Link	pending
bcli-20130930.xml	Edgar Link	completed
bcli-20130930.xsd	Edgar Link	pending
bcli-20130930_cal.xml	Edgar Link	unprocessable
bcli-20130930_def.xml	Edgar Link	unprocessable
bcli-20130930_lab.xml	Edgar Link	unprocessable
bcli-20130930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v357929_10q.htm	Edgar Link	pending
v357929_ex31-1.htm	Edgar Link	pending
v357929_ex31-2.htm	Edgar Link	pending
v357929_ex32-1.htm	Edgar Link	pending
v357929_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BCLI
BRAINSTORM CELL THERAPEUTICS INC. Stock $bcli

2013 Q3 Form 10-Q Financial Statement

#000114420413061876 Filed on November 14, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCLI BRAINSTORM CELL THERAPEUTICS INC. Stock $bcli

2013 Q3 Form 10-Q Financial Statement

#000114420413061876 Filed on November 14, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCLI
BRAINSTORM CELL THERAPEUTICS INC. Stock $bcli